4-Chloro-7-Methoxyquinoline-6-Carboxamide CAS 417721-36-9 Maʻemaʻe >98.5% (HPLC) Lenvatinib Mesylate Intermediate Factory

ʻO ka wehewehe pōkole:

Inoa: 4-Chloro-7-Methoxyquinoline-6-Carboxamide

CAS: 417721-36-9

Maʻemaʻe: >98.5% (HPLC)

ʻAno: Keʻokeʻo-keʻokeʻo a i ka pauda Melemele Māmā

Kūwaena o Lenvatinib Mesylate CAS 857890-39-2

ʻO ke kūlana kiʻekiʻe, ka hana kālepa

E-Mail: alvin@ruifuchem.com


Huahana Huahana

Nā Huahana Pili

Huahana Huahana

wehewehe:

Na Waiwai Kemika:

Inoa Kimia 4-Chloro-7-Methoxyquinoline-6-Carboxamide
Nā huaʻōlelo like 4-Chloro-7-Methoxy-6-Quinolinecarboxamide;Lenvatinib haumia 12;Lenvatinib haumia B;Lenvatinib haumia LFS-B
Helu CAS 417721-36-9
Helu CAT RF-PI1971
Kūlana Kūʻai Ma ka waihona, ka mana hana 50MT/makahiki
ʻĀpana Molekala C11H9ClN2O2
Kaumaha Molecular 236.65
Lae hehee >205℃ (Dek.)
ʻO ka mānoanoa 1.380±0.060 g/cm3
Brand Kemika Ruifu

Nā kikoʻī:

'ikamu Nā kikoʻī
Ka nana aku Pau-keʻokeʻo a i ka pauda Melemele Māmā
Maʻemaʻe / Kaʻina Hanana >98.5% (HPLC)
Nalo ma ka maloo <0.50%
Koena ma ka Ignition <0.50%
Huina paumaele <1.50%
Proton NMR Spectrum Kūlike i ka hoʻolālā
Kūlana hoʻāʻo Kūlana ʻoihana
Hoʻohana Waena o Lenvatinib Mesylate (CAS: 857890-39-2)

Pūʻolo a me ka waiho ʻana:

Pūʻolo: ʻOmole, ʻeke ʻeke Aluminum, 25kg / pahu pahu pahu, a i ʻole e like me ka makemake o ka mea kūʻai aku.

Kūlana mālama:E mālama i loko o nā pahu i hoʻopaʻa ʻia ma kahi maloʻo a maloʻo;E pale i ka malamalama a me ka wai

Pono:

1

FAQ:

Noi:

Hoʻohana nui ʻia ʻo 4-Chloro-7-Methoxyquinoline-6-Carboxamide (CAS: 417721-36-9) ma ke ʻano he waena o Lenvatinib Mesylate (CAS: 857890-39-2).Hoʻomohala ʻia e Eisai Inc., ʻo lenvatinib mesylate he mea hoʻokae endothelial growth factor receptor (VEGF) i loaʻa ka hana e kūʻē i nā subtypes VEGF 1, 2, a me 3 a ua ʻae ʻia e ka FDA ma 2015 no ka mālama ʻana i ka maʻi maʻi thyroid like ʻole. hou, metastatic, a holomua paha a ʻaʻole i pane i ka lāʻau iodine radioactive.I Mei 2016, ua ʻae ka FDA i ka lāʻau lapaʻau ma ke ʻano he hui hui me everolimus no ka mālama ʻana i ka maʻi maʻi maʻi renal cell carcinoma.No ka mea, ua manaʻo ʻia ʻo VEGF (a me ka fibroblast growth factor receptors, i kapa ʻia ʻo FGFRs) i ke kuleana i nā ala hōʻailona cardiovascular, ua manaʻo ʻia ʻo VEGF2R a me FGFR inhibition nā mea hana ma hope o ka hopena mua o ka lenvatinib mesylate, ʻo ia ka hypertension.

E kākau i kāu leka ma aneʻi a hoʻouna mai iā mākou